ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
| Revenue (Most Recent Fiscal Year) | $70.84M |
| Net Income (Most Recent Fiscal Year) | $-157.85M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.83 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -220.51% |
| Net Margin (Trailing 12 Months) | -221.97% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -55.38% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.63 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.31 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.45 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 123.88M |
| Free Float | 117.19M |
| Market Capitalization | $438.52M |
| Average Volume (Last 20 Days) | 1.33M |
| Beta (Past 60 Months) | 1.89 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 41.10% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |